The FDA will mandate its strictest safety warning on Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, ...

Risk of “acute, serious, and life-threatening” heart inflammation is now on the label of Sarepta's gene therapy for Duchenne ...

Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS ...

The FDA has added a boxed warning to Sarepta’s Duchenne gene therapy Elevidys after two teens died from liver failure and has ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such ...

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported third-quarter financial results and outlined steady progress ...

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a must-buy penny stock to buy now. On November 13, Piper Sandler analyst Biren ...

A Greer couple is hosting a fundraiser to support a costly gene editing procedure for their two children, who suffer from a ...

Thermo Fisher executives explain why they picked "Cellicon Valley" for the firm's second U.S. collaboration center and first ...

The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta caused its own stock to drop during the gene therapy maker’s safety troubles ...

Chronic diseases once meant a lifetime of management. But a new generation of cell and gene therapies is challenging that paradigm. Markets are responding. The global cell and gene therapy market is ...

New York is known to be a high-tax and higher spending state. So, it’s curious that it is attempting to violate federal law ...